Editorial: buspirone for gastroparesis-an intriguing option for a challenging condition
- PMID: 37161626
- DOI: 10.1111/apt.17511
Editorial: buspirone for gastroparesis-an intriguing option for a challenging condition
Comment on
-
Buspirone for early satiety and symptoms of gastroparesis: A multi-centre, randomised, placebo-controlled, double-masked trial (BESST).Aliment Pharmacol Ther. 2023 Jun;57(11):1272-1289. doi: 10.1111/apt.17479. Epub 2023 Apr 13. Aliment Pharmacol Ther. 2023. PMID: 37052334 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Parkman HP, Yates KP, Sarosiek I, Bulat RS, Abell TL, et al. Buspirone for early satiety and symptoms of gastroparesis: a multicentre, randomised, placebo-controlled, double-masked trial (BESST). Aliment Pharmacol Ther. 2023;57:1272-89.
-
- Tack J, Janssen P, Masaoka T, Farre R, Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2012;10(11):1239-45.
-
- Hasler WL, Wilson LA, Nguyen LA, Snape WJ, Abell TL, Koch KL, et al. Opioid use and potency are associated with clinical features, quality of life, and use of resources in patients with gastroparesis. Clin Gastroenterol Hepatol. 2019;17(7):1285-94. e1281.
-
- Pasricha PJ, Grover M, Yates KP, Abell TL, Bernard CE, Koch KL, et al. Functional dyspepsia and gastroparesis in tertiary care are interchangeable syndromes with common clinical and pathologic features. Gastroenterology. 2021;160(6):2006-17.
-
- Schol J, Wauters L, Dickman R, Drug V, Mulak A, Serra J, et al. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. United Eur Gastroenterol J. 2021;9(3):287-306.